Hydroxychloroquine treatment for primary Sjoegren's syndrome: Its effect on salivary and serum inflammatory markers

Annals of the Rheumatic Diseases

Volumn 58, Issue 4, 1999, Pages 253-256

  Tishler, Moshe ^a   Yaron, Ilana ^a   Shirazi, Idrit ^a   Yaron, Michael ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; HYALURONIC ACID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RADIOMETRY; SALIVA ANALYSIS; SJOEGREN SYNDROME; TREATMENT OUTCOME;

EID: 0032902998     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.4.253     Document Type: Article

References (15)

1. 1 Skopouli FN, Fox PC, Galanopoulou V, Atkinson JC, Jaffa ES, Moutsopoulos HM. T-cell subpopulation in labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol 1991;18:210-14.
2. 2 Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med 1988;85 (suppl 4A):62-7.
3. 3 Kruize AA, Hene RJ, Kallenberg CGN, van Bijesterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52:360-4.
4. 4 Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine; a retrospective open label study. Lupus 1996;5 (suppl 1):S31-6.
5. 5 Tishler M, Yaron I, Shirazi I, Yaron M. Saliva: an additional diagnostic tool in Sjögren's syndrome. Semin Arthritis Rheum 1997;27:173-9.
6. 6 Grisius M, Bermudez D, Fox PC. Salivary and serum interleukin-6 in Sjögren's syndrome, J Rheumatol 1997;24: 1089-91.
7. 7 Tishler M, Yaron I, Shirazi I, Yaron M. Salivary and serum hyaluronic acid levels in Sjögren's syndrome. Ann Rheum Dis 1998;57:506-8.
8. 8 Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community, Arthritis Rheum 1993;36:340-7.
9. 9 Tishler M, Yaron I, Raz A, Meyer FA, Yaron M. Salivary eicosanoid concentration in patients, with Sjögren's syndrome. Ann Rheum Dis 1996;55:202-4.
10. 10 Emlen W, Niebur J, Flanders G, Rutledge J. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: Correlation with disease. J Rheumatol 1996;23: 974-8.
11. 11 Barrera P, Boerbooms A, Janssen E, Sauerwein RW, Gallati II, Mulder J, et al. Circulatory soluble tumor necrosis factor receptors interleukin-2 receptors, tumor necrosis factor a, and interleukin-6 levels in rheumatoid arthritis. Arthritis Rheum 1993;36:1070-4.
12. 12 Madhok R, Crilly A, Wortson J, Capell H. Serum interleukin-6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4.
13. 13 Crilly A, McInness IB, McDonald AG, Watson J, Capell HA, Madhok R. Interleukin-6 and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 1995;22:224-6.
14. 14 Punzi L, Bertazzolo N, Pianon M, Michelotto M, Todesco S, Soluble interleukin-2 receptors and treatment with hydroxychloroquine in erosive osteoarthritis. J Rheumatol 1996;23:1477.
15. 15 Sperber K, Ouraiski H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin-1 alpha and IL-6 in human monocytes and T cells, J Rheumatol 1993; 20:803.